Aberrant RNA splicing is thought to play a key role in tumorigenesis. The assessment of its specific contributions limited by the complexity information derived from genome-wide array-based approaches. We describe how performing factor-specific comparisons using both tumor and cell line data sets may more readily identify physiologically relevant tumor-specific events. Affymetrix exon array glioblastoma (GBM) samples with defined polypyrimidine tract-binding protein 1 (PTBP1) levels were...

Epithelial ovarian cancer is a diverse molecular and clinical disease, yet standard treatment the same for all subtypes. TP53 mutations represent node of divergence in epithelial histologic subtypes may therapeutic opportunity expressing wild type, including most low-grade serous carcinomas, clear cell carcinomas endometrioid which approximately 25% cancer. We therefore sought to investigate Nutlin-3a—a inhibits MDM2, activates wild-type p53, induces apoptosis—as compound carcinomas. Fifteen...

// Suet-Yan Kwan 1, 2 , Xuanjin Cheng 3 Yvonne T.M. Tsang 1 Jong-Sun Choi 4 Suet-Ying Daisy I. Izaguirre Hoi-Shan David M. Gershenson Kwong-Kwok Wong Department of Gynecologic Oncology and Reproductive Medicine, The University Texas MD Anderson Cancer Center, Houston, TX, USA Biology Program, Graduate School Biomedical Sciences at Life Sciences, Chinese Hong Kong, Shatin, New Territories, Kong Center for Anti-cancer Companion Diagnostics, Institutes Entrepreneurial BioConvergence, Seoul...

PAX2 is one of nine PAX genes that regulate tissue development and cellular differentiation in embryos. However, the functional role ovarian cancer not known. Twenty-six cell lines with different histology origins were screened for expression. Two lines: RMUGL (mucinous) TOV21G (clear cell), high expression chosen further study. Knockdown these was achieved by lentiviral shRNAs targeting gene. stable knockdown cells characterized proliferation, migration, apoptosis, protein profiles, gene...

Background: The standard treatment of ovarian cancer is surgery followed by a chemotherapeutic combination consisting platinum agent, such as cisplatin and taxane-like paclitaxel. We previously observed that patients with wild-type for p53 had poorer survival rate than did those mutations. Thus, better understanding the molecular changes epithelial cells in response to could reveal novel mechanisms chemoresistance. Methods: Gene expression profiling was performed on an cell line A2780...

Abstract Ovarian cancer treatment consists of surgery followed by a chemotherapy combination entailing platinum agent (cisplatin/carboplatin) and taxane (paclitaxel). While 70-80% patients initially respond to the standard treatment, majority will relapse, these patients, 70-90% die because drug resistance. Therefore, identifying markers that can predict therapeutic response and/or targets is great interest. To identify genes involved in chemoresistance, microarray study an ovarian cell line...

Abstract Patients with ovarian serous cancer are usually younger and survive longer than patients high-grade cancer. Unfortunately, most low-grade eventually die of the disease because recurrent carcinoma is relative chemoresistant. So far, known mutations identified in carcinomas their putative precursor borderline tumors BRAF KRAS mutations. together have been approximately 60% early stage carcinomas. However, mutation rare advanced-stage To further investigate molecular pathogenesis...

Abstract The chromatin remodeling SWI/SNF complex is mutated in 20% of all cancers and ARID1A the most frequently subunit. However, tumor suppressive functions are not fully understood no feasible therapeutic strategies available for ARID1A-mutant cancers. Recent studies found that loss associated with increased phosphorylation AKT. We from a study analyzed data Project Achilles, broad shRNA screening project, PIK3CA number 2 gene essential survival cell lines compared to ARID1A-wildtype (P...

Abstract Introduction: Ovarian Clear Cell Carcinoma (OCCC) is generally aggressive and chemoresistant, with five year survival rate of approximately 40%. Recent mutation analysis has indicated a high frequency PIK3CA mutations, the gene encoding for p110α subunit in PI3K, OCCC. Aberrant signaling PI3K/AKT pathway might be linked to aggressiveness In this study, we investigated sensitivity ovarian clear cell carcinoma cells different mutations inhibitors targeting PI3K pathway. Experimental...

Abstract Ovarian cancer is the fifth most common cause of death among women. The overall five year survival 45.6% as a result late diagnosis when treatment mostly ineffective. Current consists complete resection followed by combination taxane and platinum -based chemotherapy regardless subtype. After standard treatment, 70% patients will develop chemoresistance, creating major challenge in this type cancer. Therefore, there great interest understanding mechanisms which tumors resistance....

Abstract Inactivating mutations in AT-rich interaction domain 1A (ARID1A) are most frequently found ovarian clear cell carcinomas (OCCC) and endometrioid (OEC). The functional roles of ARID1A not completely understood there limited therapeutic strategies that specifically target ARID1A-mutant cancers. Given expression is lost cancer, cannot be targeted directly novel required to In this study, drug responses between ARID1A-wildtype lines were compared using the ‘Genomics Drug Sensitivities...

Abstract Background The standard treatment for ovarian cancer is surgery, followed by chemotherapy with a platinum agent, such as cisplatin or carboplatin, and taxane, paclitaxel. We previously observed that patients was wild-type p53 had lower survival rate than did those mutations. A better understanding of the molecular changes occur in epithelial cells response to could reveal novel mechanism chemoresistance. Therefore, we might be able develop strategy overcome Methods Gene expression...